Commentary Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.33696/immunology.7.220
Spatial Architecture of the Tumor Microenvironment in Immune Checkpoint Inhibitor–Induced Hyper Progressive Bladder Cancer
Ryoichi Maenosono1,2,*, Kazuki Nishimura1,2, Kensuke Hirosuna2,3, Moritoshi Sakamoto1,2, Masahiko Ajiro1, Kazumasa Komura4, Haruhito Azuma2, Akihide Yoshimi1,*
- 1Division of Cancer RNA Research, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
- 2Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan
- 3Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan
- 4Department of Urology, Kawasaki Medical School, Kurashiki City, Okayama, Japan
Corresponding Author
Ryoichi Maenosono, ryoichi.maenosono@ompu.ac.jp;
Akihide Yoshimi, ayoshimi@ncc.go.jp
Received Date: February 13, 2025
Accepted Date: March 27, 2025
Maenosono R, Nishimura K, Hirosuna K, Sakamoto M, Ajiro M, Komura K et al. Spatial Architecture of the Tumor Microenvironment in Immune Checkpoint Inhibitor–induced Hyper progressive Bladder Cancer. J Cell Immunol. 2025;7(1):32-36.
Copyright: © 2025 Maenosono R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer
Breast cancer is the second most common cancer worldwide, affecting nearly one in eight women. Accurate cancer staging is essential for determining the patient’s prognosis and for choosing the appropriate treatment. The staging system most often used is the American Joint Committee on Cancer (AJCC) TNM system, where T refers to the size of the tumor, N refers to spread of the primary cancer to nearby lymph nodes, and M refers to the spread of metastasis to distant sites in the body.
Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery in Stage 1B2 Cervical Cancer
In 2020 we published a series of 18 patients who underwent neoadjuvant chemotherapy (NACT) and vaginal radical trachelectomy (VRT) as a fertility sparing alternative in stage 1B2 cervical cancer.
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Progress in Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Cardiotoxicity
Immune checkpoint inhibitor (ICI)-associated cardiotoxicity is a rare immune-related adverse event with high mortality. In recent years, more and more reports were reported. It is urgent to improve understanding and management. Cardiac toxicity often occurs in the early stage after ICI treatment, and its clinical manifestations are diverse and nonspecific, and its pathogenesis is still unclear. Among them, the incidence of immune myocarditis is more than 1%, which can be manifested as fulminant, acute or chronic.
Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments
Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacille Calmette-Guerin (BCG) and chemotherapy.